LTRNLantern Pharma Inc.

Nasdaq lanternpharma.com


$ 6.40 $ -0.32 (-4.76 %)    

Friday, 10-May-2024 11:03:59 EDT
QQQ $ 441.46 $ -1.46 (-0.33 %)
DIA $ 394.64 $ -0.62 (-0.16 %)
SPY $ 520.58 $ -0.94 (-0.18 %)
TLT $ 90.07 $ -0.24 (-0.27 %)
GLD $ 218.15 $ -1.63 (-0.74 %)
$ 6.81
$ 6.72
$ 0.00 x 0
$ 6.43 x 100
$ 6.22 - $ 6.79
$ 2.38 - $ 11.99
174,869
na
73.16M
$ 1.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-18-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-20-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 03-10-2022 12-31-2021 10-K
11 11-01-2021 09-30-2021 10-Q
12 07-29-2021 06-30-2021 10-Q
13 05-03-2021 03-31-2021 10-Q
14 03-10-2021 12-31-2020 10-K
15 10-29-2020 09-30-2020 10-Q
16 07-30-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lantern-pharma-q1-2024-gaap-eps-051-misses-043-estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0....

 oregon-therapeutics--lantern-pharma-launch-strategic-ai-collaboration-to-optimize-development-of-first-in-class-drug-candidate-xce853--a-potent-inhibitor-of-cancer-metabolism

Lantern Pharma Inc. (NASDAQ:LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, toda...

 hc-wainwright--co-reiterates-neutral-on-lantern-pharma

HC Wainwright & Co. analyst Emily Bodnar reiterates Lantern Pharma (NASDAQ:LTRN) with a Neutral.

 lantern-pharma-approved-to-expand-harmonic-clinical-trial-for-non-small-cell-lung-cancer-in-never-smokers-into-japan-and-taiwan

never smokers – a growing and unaddressed patient population.Dr. Yashushi Goto a leading lung cancer clinician-scientist at the...

 recap-lantern-pharma-q4-earnings
Recap: Lantern Pharma Q4 Earnings
03/18/2024 20:30:21

 lantern-pharma-q4-2023-gaap-eps-039-beats-048-estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.48...

 earnings-scheduled-for-march-18-2024

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

 lantern-pharma-earnings-preview
Lantern Pharma Earnings Preview
03/15/2024 15:00:52

 why-united-natural-foods-shares-are-trading-lower-by-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

 box-reports-upbeat-earnings-joins-american-public-education-wave-life-sciences-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.

 lantern-pharmas-ai-platform-radr-surpasses-60b-data-points-anticipates-reaching-100b-data-points-in-2024-paving-the-way-for-enhanced-cancer-therapy-innovations-and-expedited-development-timelines

The rapid growth of Lantern Pharma's AI platform could lead to accelerated development of better treatments, greater precis...

 lantern-pharma-advances-adc-program-across-multiple-solid-tumor-cancers

Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-co...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION